These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 24368400)
1. Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer. Besse B; Leighl N; Bennouna J; Papadimitrakopoulou VA; Blais N; Traynor AM; Soria JC; Gogov S; Miller N; Jehl V; Johnson BE Ann Oncol; 2014 Feb; 25(2):409-15. PubMed ID: 24368400 [TBL] [Abstract][Full Text] [Related]
2. Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer. Papadimitrakopoulou VA; Soria JC; Jappe A; Jehl V; Klimovsky J; Johnson BE J Thorac Oncol; 2012 Oct; 7(10):1594-601. PubMed ID: 22968184 [TBL] [Abstract][Full Text] [Related]
3. Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression. Reguart N; Rosell R; Cardenal F; Cardona AF; Isla D; Palmero R; Moran T; Rolfo C; Pallarès MC; Insa A; Carcereny E; Majem M; De Castro J; Queralt C; Molina MA; Taron M Lung Cancer; 2014 May; 84(2):161-7. PubMed ID: 24636848 [TBL] [Abstract][Full Text] [Related]
4. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099 [TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. Spigel DR; Burris HA; Greco FA; Shipley DL; Friedman EK; Waterhouse DM; Whorf RC; Mitchell RB; Daniel DB; Zangmeister J; Bass JD; Hainsworth JD J Clin Oncol; 2011 Jun; 29(18):2582-9. PubMed ID: 21576636 [TBL] [Abstract][Full Text] [Related]
6. A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. Lind JS; Dingemans AM; Groen HJ; Thunnissen FB; Bekers O; Heideman DA; Honeywell RJ; Giovannetti E; Peters GJ; Postmus PE; van Suylen RJ; Smit EF Clin Cancer Res; 2010 Jun; 16(11):3078-87. PubMed ID: 20395213 [TBL] [Abstract][Full Text] [Related]
7. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. Johnson BE; Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Lin CY; Marsland T; Patel T; Polikoff J; Rubin M; White L; Yang JC; Bowden C; Miller V J Clin Oncol; 2013 Nov; 31(31):3926-34. PubMed ID: 24101054 [TBL] [Abstract][Full Text] [Related]
8. Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer. Stephenson JJ; Nemunaitis J; Joy AA; Martin JC; Jou YM; Zhang D; Statkevich P; Yao SL; Zhu Y; Zhou H; Small K; Bannerji R; Edelman MJ Lung Cancer; 2014 Feb; 83(2):219-23. PubMed ID: 24388167 [TBL] [Abstract][Full Text] [Related]
9. Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib. Lara PN; Longmate J; Mack PC; Kelly K; Socinski MA; Salgia R; Gitlitz B; Li T; Koczywas M; Reckamp KL; Gandara DR Clin Cancer Res; 2015 Oct; 21(19):4321-6. PubMed ID: 26106072 [TBL] [Abstract][Full Text] [Related]
10. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. Scagliotti GV; Krzakowski M; Szczesna A; Strausz J; Makhson A; Reck M; Wierzbicki RF; Albert I; Thomas M; Miziara JE; Papai ZS; Karaseva N; Thongprasert S; Portulas ED; von Pawel J; Zhang K; Selaru P; Tye L; Chao RC; Govindan R J Clin Oncol; 2012 Jun; 30(17):2070-8. PubMed ID: 22564989 [TBL] [Abstract][Full Text] [Related]
11. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. Herbst RS; O'Neill VJ; Fehrenbacher L; Belani CP; Bonomi PD; Hart L; Melnyk O; Ramies D; Lin M; Sandler A J Clin Oncol; 2007 Oct; 25(30):4743-50. PubMed ID: 17909199 [TBL] [Abstract][Full Text] [Related]
12. Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05). Zappa F; Droege C; Betticher D; von Moos R; Bubendorf L; Ochsenbein A; Gautschi O; Oppliger Leibundgut E; Froesch P; Stahel R; Hess T; Rauch D; Schmid P; Mayer M; Crowe S; Brauchli P; Ribi K; Pless M; Lung Cancer; 2012 Dec; 78(3):239-44. PubMed ID: 23009726 [TBL] [Abstract][Full Text] [Related]
13. Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. Horn L; Gettinger S; Camidge DR; Smit EF; Janjigian YY; Miller VA; Pao W; Freiwald M; Fan J; Wang B; Chand VK; Groen HJM Lung Cancer; 2017 Nov; 113():51-58. PubMed ID: 29110849 [TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study). Yoshioka H; Azuma K; Yamamoto N; Takahashi T; Nishio M; Katakami N; Ahn MJ; Hirashima T; Maemondo M; Kim SW; Kurosaki M; Akinaga S; Park K; Tsai CM; Tamura T; Mitsudomi T; Nakagawa K Ann Oncol; 2015 Oct; 26(10):2066-72. PubMed ID: 26153496 [TBL] [Abstract][Full Text] [Related]
15. A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer. Dittrich C; Papai-Szekely Z; Vinolas N; Sederholm C; Hartmann JT; Behringer D; Kazeem G; Desaiah D; Leschinger MI; von Pawel J Eur J Cancer; 2014 Jun; 50(9):1571-80. PubMed ID: 24703574 [TBL] [Abstract][Full Text] [Related]
16. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. Reck M; van Zandwijk N; Gridelli C; Baliko Z; Rischin D; Allan S; Krzakowski M; Heigener D J Thorac Oncol; 2010 Oct; 5(10):1616-22. PubMed ID: 20736854 [TBL] [Abstract][Full Text] [Related]
17. A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer. Michael M; Pavlakis N; Clingan P; De Boer R; Johnston M; Clarke S Oncol Rep; 2012 Sep; 28(3):763-7. PubMed ID: 22710607 [TBL] [Abstract][Full Text] [Related]
18. A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer. Ciuleanu T; Tsai CM; Tsao CJ; Milanowski J; Amoroso D; Heo DS; Groen HJ; Szczesna A; Chung CY; Chao TY; Middleton G; Zeaiter A; Klingelschmitt G; Klughammer B; Thatcher N Lung Cancer; 2013 Nov; 82(2):276-81. PubMed ID: 23992877 [TBL] [Abstract][Full Text] [Related]
19. A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib. Moran T; Palmero R; Provencio M; Insa A; Majem M; Reguart N; Bosch-Barrera J; Isla D; Costa EC; Lee C; Puig M; Kraemer S; Schnell D; Rosell R Lung Cancer; 2017 Jun; 108():154-160. PubMed ID: 28625629 [TBL] [Abstract][Full Text] [Related]
20. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. Katakami N; Atagi S; Goto K; Hida T; Horai T; Inoue A; Ichinose Y; Koboyashi K; Takeda K; Kiura K; Nishio K; Seki Y; Ebisawa R; Shahidi M; Yamamoto N J Clin Oncol; 2013 Sep; 31(27):3335-41. PubMed ID: 23816963 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]